Scientists have uncovered new genetic rules that determine whether the immune system’s “killer” T cells remain powerful long-term defenders or become worn out and ineffective. By building a detailed ...
Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial dysfunction has been recognized as a hallmark of exhausted T cells in tumors. Yet ...
In a study published in Nature Aging on Nov. 26, a research team from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences revealed that aging specifically impairs ...
The ability of immune cells-particularly CD8 + T cells-to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies. However, the factors and ...
Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial dysfunction has been recognized as a hallmark of exhausted T cells in tumors. Yet ...
NCCN now recognizes BCG-unresponsive papillary-only NMIBC as eligible for nogapendekin plus BCG, broadening access beyond the ...
IL-2 is clinically validated as an immunotherapeutic, but its use is limited by toxicity issues. AZD-6750 is an approach from Astrazeneca plc that applies cis-guiding to deliver a modified IL-2 mutein ...
Peer-reviewed study demonstrates tumor-eradicating activity and durable anti-tumor immunity in multiple preclinical solid tumor models Findings ...
CEO Bob Valamehr outlined the company’s clinical and manufacturing strategy for FT819, an off-the-shelf allogeneic CAR T-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results